Lipum
14.65 SEK
-0.34 %
Less than 1K followers
LIPUM
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-0.34 %
+47.09 %
+3.90 %
+1.03 %
+22.08 %
+3.90 %
+3.51 %
-
-33.01 %
Lipum is a biopharmaceutical company. The company is in the clinical phase and specializes in the discovery and development of new treatments for chronic inflammatory diseases. The company's drug candidate is based on an antibody intended to be used in treatments to block a specific molecule in the immune system. The drug candidate is in the clinical phase with preclinical data for rheumatism. The company is also evaluating other inflammatory diseases. Lipum has its operations in Umeå.
Read moreMarket cap
310.76M SEK
Turnover
93.86K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
29/12
2025
Extraordinary general meeting '26
25/2
2026
Annual report '25
28/4
2026
Interim report Q1'26
All
Press releases
3rd party
ShowingAll content types
Lipum: Merging with Flerie - VH Corp
Västra Hamnen Market Focus: Lipum: Merging with Flerie
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools